Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NQO1 | P15559 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20787073 | 0.79 | — | — | |
| SCHEMBL5024764 | 0.71 | NLRP3 (0.32) | — | |
| Propionic Acid SCHEMBL6697023 | 0.69 | FFAR3 (0.40) | — | |
| Bromide SCHEMBL5973076 | 0.68 | — | — | |
| SCHEMBL31103 | 0.68 | — | — | |
| SCHEMBL8352566 | 0.66 | — | — | |
| Ammonia Solution, Strong SCHEMBL3583090 | 0.65 | — | — | |
| SCHEMBL7408831 | 0.64 | — | — | |
| SCHEMBL22501641 | 0.64 | TDP1 (0.55) | TDP1NQO1CHRM2CHRM4CHRM5 | |
| Bicarbonate SCHEMBL9195144 | 0.61 | TDP1 (0.69) | TDP1NQO1L3MBTL1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492425-B2 | 5-methyl-1-(naphthalen-2-yl)-1H-pyrazoles useful as sigma receptor inhibitors | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-07-23 | — | — | US | disclosed |
| US-20110118253-A1 | 5-METHYL-1-(NAPHTHALEN-2-YL)-1H-PYRAZOLES USEFUL AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-05-19 | — | — | US | disclosed |
| EP-2113501-A1 | 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118253-A1 | 5-METHYL-1-(NAPHTHALEN-2-YL)-1H-PYRAZOLES USEFUL AS SIGMA RECEPTOR INHIBITORS | SIGMAR1, OPRM1, OPRK1 | TDP1 3078/4885NQO1 569/4885CHRM2 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.